CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Taking action on drug shortages during Covid-19 – open letter
https://policybase.cma.ca/link/policy14261

POLICY TYPE  Parliamentary submission
DATE       2020-08-13
TOPICS   Pharmaceuticals, prescribing, cannabis, drugs

Dear [Name, Title],

We are writing to urge you to take action on the critical shortage of medicines in Canada during the COVID-19 pandemic. These shortages have been exacerbated by the COVID-19 pandemic; as countries around the world have been forced to develop vaccines and treatments, the demand for pharmaceuticals has increased dramatically.

As has been the case with other products, we have seen a growing trend of nations restricting access to medicines and supplies. This trend is particularly concerning given the global nature of the pandemic. The global supply chain for vaccines and treatments is already under strain, and restrictions on access to these vital goods could exacerbate the situation.

The shortages of these vital medicines are impacting patients and healthcare providers across the country. The current situation at the end of March 2020 shows how critical it is for governments to take action to ensure that the necessary supplies are available.

We urge you to take immediate action to address this critical shortage. This includes:

1. Ensuring that there is adequate funding for the production and distribution of medicines and supplies.
2. Establishing clear guidelines for the allocation of available supplies.
3. Working with international partners to ensure a coordinated global response.
4. Providing support to healthcare providers who are facing shortages.

Thank you for your attention to this critical issue.

Sincerely,

[Your Name]
[Your Position]
### Authorizing Cannabis for Medical Purposes

#### Policy document

**LAST REVIEWED**
2020-02-29

**DATE**
2015-02-28

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs

#### Documents

<table>
<thead>
<tr>
<th>Authorizing Cannabis for Medical Purposes</th>
</tr>
</thead>
<tbody>
<tr>
<td>The legalization of cannabis for medical use is a complex issue with significant implications for public health, patient care, and society. The Canadian Medical Association (CMA) has developed policies and recommendations to guide healthcare providers in this area.</td>
</tr>
</tbody>
</table>

The CMA recognizes the need for evidence-based, comprehensive, and accessible information to support clinicians in making informed decisions about the use of cannabis in medical practice. The following policies and guidelines are available for download:

- [Cannabis Policy for Healthcare Providers](https://policybase.cma.ca/policy11514)
- [Guidelines for Clinicians on the Use of Cannabis in Medicine](https://policybase.cma.ca/policy11514)
- [Cannabis and Health: A Call to Action](https://policybase.cma.ca/policy11514)

These resources provide evidence-based information on the risks and benefits of cannabis use, as well as guidance on its integration into clinical practice. Clinicians are encouraged to stay up-to-date with the latest research and guidelines to ensure safe and effective care for patients.
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE          Response to consultation
DATE                2019-05-24
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs
                     Population health, health equity, public health

Documents

CMA response:
HEALTH CANADA CONSULTATION ON REDUCING YOUTH ACCESS AND APPEAL OF VAPING PRODUCTS
May 24, 2019
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2010-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

Cannabis is a plant used for its psychoactive properties, which are known to have both medicinal and recreational uses. The Canadian Medical Association (CMA) recognizes the urgent need for a rational, evidence-based approach to the use of cannabis for medical purposes. This policy provides guidance for healthcare providers on the use of cannabis for medical purposes, including the assessment of patients, the selection of therapeutic options, and the monitoring of outcomes. It is based on the best available evidence and reflects the views of the CMA's Board of Directors, Council, and members.

The use of cannabis for medical purposes should be limited to cases where traditional treatments have failed or are inappropriate. Healthcare providers should ensure that patients are aware of the potential risks and benefits associated with the use of cannabis and its derivatives.

CMA POLICY

Cannabis for Medical Purposes

Cannabis is a plant used for its psychoactive properties, which are known to have both medicinal and recreational uses. The Canadian Medical Association (CMA) recognizes the urgent need for a rational, evidence-based approach to the use of cannabis for medical purposes. This policy provides guidance for healthcare providers on the use of cannabis for medical purposes, including the assessment of patients, the selection of therapeutic options, and the monitoring of outcomes. It is based on the best available evidence and reflects the views of the CMA's Board of Directors, Council, and members.

The use of cannabis for medical purposes should be limited to cases where traditional treatments have failed or are inappropriate. Healthcare providers should ensure that patients are aware of the potential risks and benefits associated with the use of cannabis and its derivatives.

1. Increase awareness of the benefits of cannabis for medical purposes, particularly for the treatment of pain, nausea, and glaucoma.
2. Provide education and training to healthcare providers on the use of cannabis for medical purposes.
3. Promote research on the therapeutic effects of cannabis for medical purposes.
4. Encourage the development of safe and effective cannabis products for medical use.
5. Advocacy for the decriminalization of cannabis for medical purposes.

Cannabis for Medical Purposes

Cannabis is a plant used for its psychoactive properties, which are known to have both medicinal and recreational uses. The Canadian Medical Association (CMA) recognizes the urgent need for a rational, evidence-based approach to the use of cannabis for medical purposes. This policy provides guidance for healthcare providers on the use of cannabis for medical purposes, including the assessment of patients, the selection of therapeutic options, and the monitoring of outcomes. It is based on the best available evidence and reflects the views of the CMA's Board of Directors, Council, and members.

The use of cannabis for medical purposes should be limited to cases where traditional treatments have failed or are inappropriate. Healthcare providers should ensure that patients are aware of the potential risks and benefits associated with the use of cannabis and its derivatives.

1. Increase awareness of the benefits of cannabis for medical purposes, particularly for the treatment of pain, nausea, and glaucoma.
2. Provide education and training to healthcare providers on the use of cannabis for medical purposes.
3. Promote research on the therapeutic effects of cannabis for medical purposes.
4. Encourage the development of safe and effective cannabis products for medical use.
5. Advocacy for the decriminalization of cannabis for medical purposes.

Cannabis for Medical Purposes

Cannabis is a plant used for its psychoactive properties, which are known to have both medicinal and recreational uses. The Canadian Medical Association (CMA) recognizes the urgent need for a rational, evidence-based approach to the use of cannabis for medical purposes. This policy provides guidance for healthcare providers on the use of cannabis for medical purposes, including the assessment of patients, the selection of therapeutic options, and the monitoring of outcomes. It is based on the best available evidence and reflects the views of the CMA's Board of Directors, Council, and members.

The use of cannabis for medical purposes should be limited to cases where traditional treatments have failed or are inappropriate. Healthcare providers should ensure that patients are aware of the potential risks and benefits associated with the use of cannabis and its derivatives.

1. Increase awareness of the benefits of cannabis for medical purposes, particularly for the treatment of pain, nausea, and glaucoma.
2. Provide education and training to healthcare providers on the use of cannabis for medical purposes.
3. Promote research on the therapeutic effects of cannabis for medical purposes.
4. Encourage the development of safe and effective cannabis products for medical use.
5. Advocacy for the decriminalization of cannabis for medical purposes.

Cannabis for Medical Purposes

Cannabis is a plant used for its psychoactive properties, which are known to have both medicinal and recreational uses. The Canadian Medical Association (CMA) recognizes the urgent need for a rational, evidence-based approach to the use of cannabis for medical purposes. This policy provides guidance for healthcare providers on the use of cannabis for medical purposes, including the assessment of patients, the selection of therapeutic options, and the monitoring of outcomes. It is based on the best available evidence and reflects the views of the CMA's Board of Directors, Council, and members.

The use of cannabis for medical purposes should be limited to cases where traditional treatments have failed or are inappropriate. Healthcare providers should ensure that patients are aware of the potential risks and benefits associated with the use of cannabis and its derivatives.

1. Increase awareness of the benefits of cannabis for medical purposes, particularly for the treatment of pain, nausea, and glaucoma.
2. Provide education and training to healthcare providers on the use of cannabis for medical purposes.
3. Promote research on the therapeutic effects of cannabis for medical purposes.
4. Encourage the development of safe and effective cannabis products for medical use.
5. Advocacy for the decriminalization of cannabis for medical purposes.
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE: Policy document
LAST REVIEWED: 2019-03-03
DATE: 2011-05-28
REPLACES: Medication use and seniors
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  
Policy document

LAST REVIEWED  
2019-03-03

DATE  
2012-12-08

TOPICS  
Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE  Response to consultation
DATE  2019-02-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE: Response to consultation
DATE: 2018-12-04
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE
Response to consultation

DATE
2018-10-02

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE: Response to consultation
DATE: 2018-09-06
TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE
Policy endorsement

DATE
2018-08-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

**POLICY TYPE**  Response to consultation

**DATE**  2018-08-14

**TOPICS**  Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE: Response to consultation

DATE: 2018-07-18

TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA response:

HEALTH CANADA CONSULTATION ON RESTRICTION OF MARKETING AND ADVERTISING OF OPIOIDS

Jun 18, 2018
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE
Parliamentary submission

DATE
2018-04-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA's Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

POLICY TYPE     Parliamentary submission
DATE            2018-02-15
TOPICS          Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE  2018-01-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents